Washington Rheumatology Alliance 14th Annual Conference
September 17-19, 2021
Sleeping Lady Mountain Resort
7375 Icicle Road
Leavenworth, WA 98826
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Community Health Network and the Washington Rheumatology Alliance. Community Health Network is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.
Community Health Network designates this Live Activity for a maximum of 7.0 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Saturday, September 18, 2021
Osteoporosis Update: Denosumab Transition, Teriparatide Label Change and Much More, Robin Dore, MD
Immunosuppression: Is It All in Your Head? Robert Ettlinger, MD, FACP
Pulmonary Involvement in Rheumatic Diseases, Robin Dore, MD
Steroid Safety: Adrenal Insufficiency “An Endocrine Perspective,” Lynn Kohlmeier, MD
Improving Recognition and Management of EGPA: A Multidisciplinary Approach to Individualizing Treatment, Michael E. Wechsler, MD
COVID Vaccines: The Nuanced and the Confounding, Sasha E. Larsen Akins, PhD
Sunday, September 19, 2021
Not So Rare “Rare Metabolic Bone Diseases” in Rheumatology, Lynn Kohlmeier, MD
Sponsors & Exhibitors
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into three core global business units: Sanofi Genzyme, Sanofi Pasteur, and General Medicines. Consumer Healthcare is a standalone business unit. Please visit https://www.sanofi.com to learn more.
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Our business is organized to deliver our strategic prioritizes sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
Aurinia is a biopharmaceutical company focused on developing therapies for patient populations impacted by serious diseases with a high unmet medical need. Aurinia recently received FDA approval for their first commercially available drug product, LUPKYNIS. LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN). Please visit https://lupkynispro.com to learn more.